- Home
- MBRX vs RMCO Comparison
MBRX vs RMCO Comparison
Compare MBRX & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- RMCO
- Stock Information
- Founded
- MBRX 2015
- RMCO 2021
- Country
- MBRX United States
- RMCO United States
- Employees
- MBRX N/A
- RMCO N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- RMCO Multi-Sector Companies
- Sector
- MBRX Health Care
- RMCO Miscellaneous
- Exchange
- MBRX Nasdaq
- RMCO Nasdaq
- Market Cap
- MBRX 12.9M
- RMCO 14.9M
- IPO Year
- MBRX 2016
- RMCO N/A
- Fundamental
- Price
- MBRX $0.31
- RMCO $1.25
- Analyst Decision
- MBRX Strong Buy
- RMCO
- Analyst Count
- MBRX 3
- RMCO 0
- Target Price
- MBRX $5.33
- RMCO N/A
- AVG Volume (30 Days)
- MBRX 5.2M
- RMCO 18.6K
- Earning Date
- MBRX 08-13-2025
- RMCO 08-14-2025
- Dividend Yield
- MBRX N/A
- RMCO N/A
- EPS Growth
- MBRX N/A
- RMCO N/A
- EPS
- MBRX N/A
- RMCO N/A
- Revenue
- MBRX N/A
- RMCO $1,568,212.00
- Revenue This Year
- MBRX N/A
- RMCO N/A
- Revenue Next Year
- MBRX N/A
- RMCO N/A
- P/E Ratio
- MBRX N/A
- RMCO N/A
- Revenue Growth
- MBRX N/A
- RMCO 204.08
- 52 Week Low
- MBRX $0.25
- RMCO $0.74
- 52 Week High
- MBRX $4.71
- RMCO $1.32
- Technical
- Relative Strength Index (RSI)
- MBRX 24.39
- RMCO 62.27
- Support Level
- MBRX $0.25
- RMCO $1.19
- Resistance Level
- MBRX $0.42
- RMCO $1.30
- Average True Range (ATR)
- MBRX 0.06
- RMCO 0.06
- MACD
- MBRX -0.03
- RMCO 0.02
- Stochastic Oscillator
- MBRX 13.07
- RMCO 80.00
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.